News
April 16, 2024
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
April 16, 2024
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
April 8, 2024
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
April 2, 2024
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
March 6, 2024
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 28, 2024
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 26, 2024
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
February 14, 2024
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
February 6, 2024
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
January 29, 2024